12:00 AM
 | 
May 21, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Prochymal remestemcel-L regulatory update

Health Canada granted conditional approval to Prochymal remestemcel-L from Osiris to manage acute graft-versus-host disease (GvHD) in children who fail to respond to steroids. Osiris is required to conduct a confirmatory trial of the IV formulation of mesenchymal stem cells...

Read the full 176 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >